Improving Accessibility & Affordability of Existing Biological Drugs
Prestige Biopharma aims to expand patient access to treatment by providing safe, quality and affordable biomedicines. Our biosimilar portfolio consists of 12 pipelines, including our HD201 (trastuzumab) in completion of Phase III, HD204 (bevacizumab) in Phase III and PBP1502 (adalimumab) in Phase I.

HD201
Trastuzumab Biosimilar
Breast Cancer, Gastric Cancer

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


HD204
Bevacizumab Biosimilar
Solid Tumors

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP1502
Adalimumab Biosimilar
Arthritis

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP1601
Denosumab Biosimilar
Bone Loss, Osteoporosis

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP1602
Aflibercept Biosimilar
Macular Edema, Metastatic Colorectal Cancer, Retinopathy

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP1603
Eculizumab Biosimilar
Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP1701
Ipilimumab Biosimilar
Metastatic / Unresectable Melanoma

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP1801
Pertuzumab Biosimilar
Breast Cancer

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP2001
Ramucirumab Biosimilar
Metastatic / Gastric Junction Adenocarcinoma

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP2002
Natalizumab Biosimilar
Active Crohn’s Disease

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP2101
Nivolumab Biosimilar
Metastatic Urothelial Carcinoma

Discovery

Preclinical

Phase I

Phase III

Filing

Approval


PBP2102
Pembrolizumab Biosimilar
Metastatic / Unresectable Melanoma

Discovery

Preclinical

Phase I

Phase III

Filing

Approval